|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALZ Talks: Learn about new Alzheimer’s treatment and next steps
|
|
|
ALZ Talks — our monthly online series featuring conversations about Alzheimer’s and other dementias — will provide an update on the recently approved drug lecanemab (Leqembi™). Association experts will review details about this new treatment, how it is administered, next steps around access, and its potential benefits and side effects.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ask Congress to ensure access to approved Alzheimer’s treatments
|
|
|
The Centers for Medicare & Medicaid Services (CMS) is restricting access to U.S. Food and Drug Administration (FDA)-approved treatments for Alzheimer's. People living with Alzheimer’s should have FDA-approved treatments covered by Medicare just as those facing other diseases do. Take action by asking Congress to call on CMS to change this decision.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
My Preferences:
|
Unsubscribe
To stop receiving our weekly e-newsletter, simply unsubscribe.
|
|
Subscribe
Was this e-newsletter forwarded to you? Subscribe to get it weekly.
|
|
|
|
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.
Alzheimer's Association Home Office 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601 © 2023 Alzheimer's Association. All rights reserved. www.alz.org | 800.272.3900.
|
